Table 3.
Number and severity of rejections since heart transplantation till the last follow-up as well as immunological and inflammatory factors at follow-up in survivors and non-survivors.
| Survivors (group 1) N = 133 |
Non-survivors (group 2) N = 39 |
P | |
|---|---|---|---|
| Rejections | 73 (54.9%) | 24 (61.5%) | 0.461 |
| Rejection stage: | 0.299 | ||
| 1 | 31 (23.3%) | 7 (17.9%) | |
| 2 | 39 (29.3%) | 14 (35.9%) | |
| 3 | 3 (2.3%) | 3 (7.7%) | |
| Rejections requiring therapy | 45 (33.8%) | 18 (46.2%) | 0.160 |
| Rejections requiring therapy under 24 months after heart transplantation | 40 (88.9%) | 13 (72.2%) | 0.102 |
| Leukocytes (G/L) | 7.3 ± 2.5 | 8.2 ± 2.7 | 0.048* |
| Lymphocytes [cells/μL] | 1542.6 ± 687.3 | 1519.1 ± 960.0 | 0.865 |
| CD3 [cells/μL] | 1217.7 ± 634.6 | 1212.8 ± 894.2 | 0.969 |
| CD3 [%] | 77.3 ± 11.3 | 78.0 ± 11.3 | 0.731 |
| CD4 [cells/μL] | 700.1 ± 325.2 | 616.4 ± 400.0 | 0.183 |
| CD4 [%] | 46.2 ± 10.9 | 42.0 ± 11.8 | 0.042* |
| CD8 [cells/μL] | 480.7 ± 427.7 | 569.4 ± 545.4 | 0.287 |
| CD8 [%] | 28.7 ± 13.5 | 34.2 ± 16.3 | 0.035* |
| CD4/CD8 | 2.3 ± 2.0 | 1.7 ± 1.2 | 0.087 |
| CD19 [cells/μL] | 89.7 ± 79.6 | 73.1 ± 86.3 | 0.262 |
| CD19 [%] | 6.0 ± 5.0 | 4.5 ± 3.5 | 0.080 |
| Natural killers [cells/μL] | 224.9 ± 151.1 | 214.1 ± 156.4 | 0.696 |
| Natural killers [%] | 16.0 ± 10.2 | 15.8 ± 10.3 | 0.939 |
| Interleukin-6 [pg/mL] | 9.5±9.8 | 14.2±20.3 | 0.047* |
| C-reactive protein [mg/dL] | 0.8±0.9 | 1.7±2.6 | 0.001* |
All percentages are expressed as the number of distinct lymphocyte subsets divided by the number of all lymphocytes multiplied by 100%. Data are presented as a mean ± standard deviation or number (percentage);
*
p < 0.05 (significant)